Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Mirati Therapeutics Inc is a biotechnology business based in the US. Mirati Therapeutics shares (MRTX) are listed on the NASDAQ and all prices are listed in US Dollars. Mirati Therapeutics employs 199 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$190.29|
|52-week range||$131.47 - $249.42|
|50-day moving average||$170.59|
|200-day moving average||$161.56|
|Wall St. target price||$222.67|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-10.04|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||6.74%|
|1 month (2021-09-24)||14.38%|
|3 months (2021-07-23)||21.10%|
|6 months (2021-04-23)||22.25%|
|1 year (2020-10-23)||5.60%|
|2 years (2019-10-24)||149.76%|
|3 years (2018-10-24)||494.66%|
|5 years (2016-10-24)||3,490.38%|
|Revenue TTM||$13.1 million|
|Gross profit TTM||$13.4 million|
|Return on assets TTM||-30.43%|
|Return on equity TTM||-56.58%|
|Market capitalisation||$9.2 billion|
TTM: trailing 12 months
There are currently 4.0 million Mirati Therapeutics shares held short by investors – that's known as Mirati Therapeutics's "short interest". This figure is 20.2% up from 3.3 million last month.
There are a few different ways that this level of interest in shorting Mirati Therapeutics shares can be evaluated.
Mirati Therapeutics's "short interest ratio" (SIR) is the quantity of Mirati Therapeutics shares currently shorted divided by the average quantity of Mirati Therapeutics shares traded daily (recently around 573623.85714286). Mirati Therapeutics's SIR currently stands at 7. In other words for every 100,000 Mirati Therapeutics shares traded daily on the market, roughly 7000 shares are currently held short.
However Mirati Therapeutics's short interest can also be evaluated against the total number of Mirati Therapeutics shares, or, against the total number of tradable Mirati Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Mirati Therapeutics's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Mirati Therapeutics shares in existence, roughly 80 shares are currently held short) or 0.1164% of the tradable shares (for every 100,000 tradable Mirati Therapeutics shares, roughly 116 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Mirati Therapeutics.
Find out more about how you can short Mirati Therapeutics stock.
We're not expecting Mirati Therapeutics to pay a dividend over the next 12 months.
Mirati Therapeutics's shares were split on a 1:50 basis on 2 July 2013. So if you had owned 50 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Mirati Therapeutics shares – just the quantity. However, indirectly, the new 4900% higher share price could have impacted the market appetite for Mirati Therapeutics shares which in turn could have impacted Mirati Therapeutics's share price.
Over the last 12 months, Mirati Therapeutics's shares have ranged in value from as little as $131.47 up to $249.42. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Mirati Therapeutics's is 1.3794. This would suggest that Mirati Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Mirati Therapeutics, Inc. , a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase I/II clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase II clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and a clinical collaboration agreement with Novartis Pharmaceuticals Corporation. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.